Ivermectin vs. lindane in the treatment of scabies

• Autorzy: Goldust M. , Rezaee E. , Raghifar R. , Naghavi-Behzad M.
• Języki publikacji: EN

Abstrakty

EN

Scabies is commonly treated with acaricides but the treatment of choice is still controversial. This study aimed at comparing the efficacy of oral ivermectin vs. lindane lotion 1% for the treatment of scabies. Four hundred fourty patients with scabies were enrolled, and randomized into two groups: the first group received a single dose of oral ivermectin 200 μg/kg body weight, and the second group were treated with two applications of topical lindane lotion 1%, with a 1-week interval. Treatment was evaluated at intervals of 2 and 4 weeks, and if there was treatment failure at the 2-week follow-up, treatment was repeated. Single dose of oral ivermectin provided a cure rate of 63.6% at the 2-week follow-up, which increased to 81.8% at the 4-week follow-up after repeating the treatment. Treatment with two applications of lindane lotion 1%, with a 1-week interval between them, was effective in 45.4% of patients at the 2-week follow-up, which increased to 63.6% at the 4-week follow-up after this treatment was repeated. Single dose ivermectin was as effective as two applications of lindane lotion 1% at the 2-week follow-up. After repeating the treatment, ivermectin was superior to lindane lotion 1% at the 4-week follow up.

Słowa kluczowe

EN

ivermectin; oral ivermectin; treatment; scabies; lindane; skin disease; human disease

• Wydawca: -
• Czasopismo: Annals of Parasitology
• Rocznik: 2013
• Tom: 59
• Numer: 1
• Opis fizyczny: p.37-41,ref.

Twórcy

autor

Goldust M.

• Student Research Committee, Tabriz University of Medical Sciences, Iran

autor

Rezaee E.

• Department of Medicinal Chemistry, Shahid Beheshti University of Medical Sciences, Teheran, Iran

autor

Raghifar R.

• Student Research Committee, Tabriz University of Medical Sciences, Iran

autor

Naghavi-Behzad M.

• Medical Philosophy and History Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

Bibliografia

• [1] Fernandez-Sanchez M., Saeb-Lima M., Alvarado-de la Barrera C., Reyes-Teran G. 2012. Crusted scabiesassociated immune reconstitution inflammatory syndrome. BMC Infectious Diseases 12: 323.
• [2] Talukder K., Talukder M.Q., Farooque M.G., Khairul M., Sharmin F., Jerin I., Rahman M.A. 2012. Controlling scabies in madrasahs (Islamic religious schools) in Bangladesh. Public Health 127: 83-91.
• [3] Mohebbipour A., Saleh P., Goldust M., Amirnia M., Zadeh Y.J., Mohamadi R.M., Rezaee E. 2012. Treatment of scabies: comparison of Ivermectin vs. Lindane Lotion 1%. Acta Dermatovenerologica Croatica 20: 251-255.
• [4] Gunning K., Pippitt K., Kiraly B., Sayler M. 2012. Pediculosis and scabies: treatment update. American Family Physician 86: 535-541.
• [5] Poetzsch B. 2012. Lice infestations and scabies. JAAPA 25: 58, 60.
• [6] Goldust M., Ranjkesh M.R., Amirinia M., Golforoushan F., Rezaee E., Rezazadeh Saatlou M.A. 2012. Sertaconazole 2 % cream vs. hydrocortisone 1% cream in the treatment of seborrheic dermatitis. Journal of Dermatological Treatment doi: 10.3109/09546634.2012.755251.
• [7] Goldust M., Golforoushan F., Ranjkesh M.R., Babae N.S., Rezaee E. 2012. Comparative trial of Permethrin 5% vs. Lindane 1% for the treatment of scabies. Journal of Dermatological Treatment doi: 10.3109/09546634.2012.723122.
• [8] Chhaiya S.B., Patel V.J., Dave J.N., Mehta D.S., Shah H.A. 2012. Comparative efficacy and safety of topical permethrin, topical ivermectin, and oral ivermectin in patients of uncomplicated scabies. Indian Journal of Dermatology, Venereology and Leprology 78: 605-610.
• [9] Wolf R., Davidovici B. 2010. Treatment of scabies and pediculosis: facts and controversies. Clinics in Dermatology 28: 511-518.
• [10] Mounsey K., Ho M.F., Kelly A., Willis C., Pasay C., Kemp D.J., McCarthy J.S., Fischer K. 2010. A tractable experimental model for study of human and animal scabies. PLoS Neglected Tropical Diseases 4: e756.
• [11] Ly F., Caumes E., Ndaw C.A., Ndiaye B., Mahe A. 2009. Ivermectin versus benzyl benzoate applied once or twice to treat human scabies in Dakar, Senegal: a randomized controlled trial. Bulletin of the WHO 87: 424-430.
• [12] Modamio P., Lastra C.F., Sebarroja J., Marino E.L. 2009. Stability of 5% permethrin cream used for scabies treatment. Pediatric Infectious Disease Journal 28: 668.
• [13] Goldust M., Rezaee E., Hemayat S. 2012. Treatment of scabies: comparison of permethrin 5% versus ivermectin. Journal of Dermatology 39: 545-547.
• [14] Oyelami O.A., Onayemi A., Oyedeji O.A., Adeyemi L.A. 2009. Preliminary study of effectiveness of aloe vera in scabies treatment. Phytotherapy Research 23: 1482-1484.
• [15] Nolan K., Kamrath J., Levitt J. 2012. Lindane toxicity: a comprehensive review of the medical literature. Pediatric Dermatology 29: 141-146.
• [16] Jin S.P., Choi J.E., Won C.H., Cho S. 2009. Scabies in a 2-month-old infant successfully treated with Lindane. Annals of Dermatology 21: 200-202.
• [17] Worth C., Heukelbach J., Fengler G., Walter B., Liesenfeld O., Hengge U., Feldmeier H. 2012. Acute morbidity associated with scabies and other ectoparasitoses rapidly improves after treatment with ivermectin. Pediatric Dermatology 29: 430-436.
• [18] Gonzalez P., Gonzalez F.A., Ueno K. 2012. Ivermectin in human medicine, an overview of the current status of its clinical applications. Current Pharmaceutical Biotechnology 13: 1103-1119.
• [19] Hengge U.R., Currie B.J., Jager G., Lupi O., Schwartz R.A. 2006. Scabies: a ubiquitous neglected skin disease. Lancet Infectious Diseases 6: 769-779.
• [20] van den Hoek J.A., van de Weerd J.A., Baayen T.D., Molenaar P.M., Sonder G.J., van Ouwerkerk I.M., de Vries H.J. 2008. A persistent problem with scabies in and outside a nursing home in Amsterdam: indications for resistance to lindane and ivermectin. Eurosurveillance 13 (48): 1-2.
• [21] Buehlmann M., Beltraminelli H., Strub C., Bircher A., Jordan X., Battegay M., Itin P., Widmer A.F. 2009. Scabies outbreak in an intensive care unit with 1,659 exposed individuals-key factors for controlling the outbreak. Infection Control and Hospital Epidemiology 30: 354-360.
• [22] Diamantis S.A., Morrell D.S., Burkhart C.N. 2003. Pediatric infestations. Pediatric Annals 38: 326-332.
• [23] Walker G., Johnstone P. 2003. Scabies. Clinical Evidence 10: 1910-1918.
• [24] Humphreys E.H., Janssen S., Heil A., Hiatt P., Solomon G., Miller M.D. 2008. Outcomes of the California ban on pharmaceutical lindane: clinical and ecologic impacts. Environmental Health Perspectives 116: 297-302.
• [25] Burkhart C.G., Burkhart C.N. 2004. Oral ivermectin for Phthirus pubis. Journal of the American Academy of Dermatology 51: 1037-1038.
• [26] Chaurasia R.C. 2007. Ivermectin – antiscabies chemotherapeutic agent used in masses. Journal of Indian Medical Association 105: 99.
• [27] Borkowski P.K. 2007. Parasitophobic patient suffering from scabies treated with ivermectin – a case report. Przegląd Epidemiologiczny 61: 103-106 (In Polish).
• [28] Fox L.M. 2006. Ivermectin: uses and impact 20 years on. Current Opinion in Infectious Diseases 19: 588-593.
• [29] Sparsa A., Bonnetblanc J.M., Peyrot I., Loustaud-Ratti V., Vidal E., Bedane C. 2006. Systemic adverse reactions with ivermectin treatment of scabies. Annales de Dermatologie et de Venereologie 133: 784-787 (In French).
• [30] Chhaiya S.B., Patel V.J., Dave J.N., Mehta D.S., Shah H.A. 2012. Comparative efficacy and safety of topical permethrin, topical ivermectin, and oral ivermectin in patients of uncomplicated scabies. Indian Journal of Dermatology, Venereology and Leprology 78: 605-610.
• [31] Madan V., Jaskiran K., Gupta U., Gupta D.K. 2001. Oral ivermectin in scabies patients: a comparison with 1% topical lindane lotion. Journal of Dermatology 28: 481-484.